Asprosin, a Fasting-Induced Glucogenic Protein Hormone
Author(s) -
Chase Romere,
Clemens Duerrschmid,
Juan C. Bournat,
Petra Constable,
Mahim Jain,
Fan Xia,
Pradip Saha,
Maria del Solar,
Bokai Zhu,
Brian York,
Poonam Sarkar,
David A. Rendon,
M. Waleed Gaber,
Scott A. LeMaire,
Joseph S. Coselli,
Dianna M. Milewicz,
V. Reid Sutton,
Nancy F. Butte,
David D. Moore,
Atul R. Chopra
Publication year - 2016
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2016.02.063
Subject(s) - medicine , endocrinology , biology , hormone , insulin , adipose tissue , insulin resistance
Hepatic glucose release into the circulation is vital for brain function and survival during periods of fasting and is modulated by an array of hormones that precisely regulate plasma glucose levels. We have identified a fasting-induced protein hormone that modulates hepatic glucose release. It is the C-terminal cleavage product of profibrillin, and we name it Asprosin. Asprosin is secreted by white adipose, circulates at nanomolar levels, and is recruited to the liver, where it activates the G protein-cAMP-PKA pathway, resulting in rapid glucose release into the circulation. Humans and mice with insulin resistance show pathologically elevated plasma asprosin, and its loss of function via immunologic or genetic means has a profound glucose- and insulin-lowering effect secondary to reduced hepatic glucose release. Asprosin represents a glucogenic protein hormone, and therapeutically targeting it may be beneficial in type II diabetes and metabolic syndrome.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom